CIHR 5-Year Evaluation Schedule (2008-2009 – 2012-2013)

The following schedules outline the timing of program evaluations at CIHR for Fiscal Year 2008/09 through to 2012/13. The proposed evaluations generally require six months for planning and one full year for the conduct of the study, at the end of which an evaluation report is expected. The programs are listed by Program Activity Architectures (PAA) number followed by the program title. The timelines are indicated in brackets (Q1 = first quarter, etc). These are estimates based on the current resources available to the Evaluation Unit and the governance structures in place at CIHR. The evaluation commitments carried over from Year 2007/08, as they relate to the PAA classification are identified with an asterisk *.

2008-2009

1. Planning an evaluation

External Review of CIHR (Q2, Q3, Q4)
1.1.1 Open Operating Grant Program (Q2, Q3)
1.1.2 Randomized Controlled Trials Program (Q2, Q3)
1.1.3 Team Grant Program (Q1, Q2)
1.2.4 Pandemic Preparedness Research Initiative (Q2, Q3)
2.1.3 Canada Research Chairs Grant Program (Q3, Q4)

2. Ongoing Evaluation

1.1.1 Open Operating Grant Program (Q4)
1.1.2 Randomized Controlled Trials Program (Q4)
1.1.3 Team Grant Program (Q3, Q4)
1.2.4 Pandemic Preparedness Research Initiative (Q4)

3. Evaluation Report

2.1.2 Training Support Programs (Q2)*
2.1.4 Canada Graduate Scholarships Program (Q4)*
2.1.6 Strategic Training Support Programs (Q2)*
2.4    Ethical, Legal, Social Issues (Q3)*

2009-2010

1. Planning an evaluation

External Review of CIHR (Q1, Q2, Q3)
1.2.1 Strategic Priority Operating Grant Programs (Q1, Q2)
1.2.2 Large Strategic Initiatives Program (Q1, Q2)
2.1.1 Salary Support Programs (Q2, Q3)
2.1.5 Strategic Salary Support Programs (Q2, Q3)
2.2.1 Research Resources, Collaboration (Q1, Q2)

2. Ongoing Evaluation

External Review of CIHR (Q4)
1.1.1 Open Operating Grant Program (Q1, Q2, Q3)
1.1.2 Randomized Controlled Trials Program (Q1, Q2, Q3)
1.1.3 Team Grant Program (Q1, Q2)
1.2.1 Strategic Priority Operating Grant Programs (Q3, Q4)
1.2.2 Large Strategic Initiatives Program (Q3, Q4)
1.2.4 Pandemic Preparedness Research Initiative (Q1)
2.1.1 Salary Support Programs (Q4)
2.1.3 Canada Research Chairs Grant Program (Q1, Q2, Q3, Q4)
2.1.5 Strategic Salary Support Programs (Q4)
2.2.1 Research Resources, Collaboration (Q3, Q4)

3. Evaluation Report

1.1.1 Open Operating Grant Program (Q4)
1.1.2 Randomized Controlled Trials Program (Q4)
1.1.3 Team Grant Program (Q3)
1.2.4 Pandemic Preparedness Research Initiative (Q2)

2010-2011

1. Planning an evaluation

1.1.1 Open Operating Grant Program (Q1)
1.2.3 HIV/AIDS Research Initiative (Q2, Q3)
1.2.5 Expensive Drugs for Rare Diseases Research Initiative (Q1, Q2)
2.3.2 Partnership Programs (Q1, Q2)
3.1.1 Knowledge Translation Program (Q2, Q3)
3.2.1 Commercialization Funding Programs (Q2, Q3)

2. Ongoing Evaluation

External Review of CIHR (Q1, Q2)
1.1.1 Open Operating Grant Program (Q2, Q3, Q4)
1.2.1 Strategic Priority Operating Grant Programs (Q1, Q2)
1.2.2 Large Strategic Initiatives Program (Q1, Q2)
1.2.3 HIV/AIDS Research Initiative (Q4)
1.2.5 Expensive Drugs for Rare Diseases Research Initiative (Q3, Q4)
2.1.1 Salary Support Programs (Q1, Q2, Q3)
2.1.5 Strategic Salary Support Programs (Q1, Q2 Q3)
2.2.1 Research Resources, Collaboration (Q1, Q2)
2.3.2 Partnership Programs (Q3, Q4)
3.1.1 Knowledge Translation Program (Q4)
3.2.1 Commercialization Funding Programs (Q4)

3. Evaluation Report

External Review of CIHR (Q3)
1.2.1 Strategic Priority Operating Grant Programs (Q3)
1.2.2 Large Strategic Initiatives Program (Q3)
2.1.1 Salary Support Programs (Q4)
2.1.3 Canada Research Chairs Grant Program (Q1)
2.1.5 Strategic Salary Support Programs (Q4)
2.2.1 Research Resources, Collaboration (Q3)

2011-2012

1. Planning an evaluation

1.1.1 Open Operating Grant Program (Q3)
1.2.6 National Anti-Drug Strategy Treatment Research Initiative (Q1, Q2)
2.1.2 Training Support Programs (Q1, Q2)
2.1.4 Canada Graduate Scholarships Program (Q1, Q2)
2.1.6 Strategic Training Support Programs (Q1, Q2)
2.3.1 Institute Support Grants (Q3, Q4)
3.1.2 Networks of Centers of Excellence Program (Q2, Q3)

2. Ongoing Evaluation

1.1.1 Open Operating Grant Program (Q1, Q4)
1.2.3 HIV/AIDS Research Initiative (Q1, Q2, Q3)
1.2.5 Expensive Drugs for Rare Diseases Research Initiative (Q1)
1.2.6 National Anti-Drug Strategy Treatment Research Initiative (Q3, Q4)
2.1.2 Training Support Programs (Q3, Q4)
2.1.4 Canada Graduate Scholarships Program (Q3, Q4)
2.1.6 Strategic Training Support Programs (Q3, Q4)
2.3.2 Partnership Programs (Q1, Q2)
3.1.1 Knowledge Translation Program (Q1, Q2, Q3)
3.1.2 Networks of Centers of Excellence Program (Q4)
3.2.1 Commercialization Funding Programs (Q1, Q2, Q3)

3. Evaluation Report

1.1.1 Open Operating Grant Program (Q2)
1.2.3 HIV/AIDS Research Initiative (Q4)
2.3.2 Partnership Programs (Q3)
3.1.1 Knowledge Translation Program (Q4)
3.2.1 Commercialization Funding Programs (Q4)

2012-2013

1. Planning an evaluation

2.4 Ethical, Legal, Social Issues (Q1, Q2)

2. Ongoing Evaluation

1.1.1 Open Operating Grant Program (Q1, Q2, Q3)
1.2.6 National Anti-Drug Strategy Treatment Research Initiative (Q1, Q2)
2.1.2 Training Support Programs (Q1, Q2)
2.1.4 Canada Graduate Scholarships Program (Q1, Q2)
2.1.6 Strategic Training Support Programs (Q1, Q2)
2.3.1 Institute Support Grants (Q1, Q2, Q3, Q4)
2.4    Ethical, Legal, Social Issues (Q3, Q4)
3.1.2 Networks of Centers of Excellence Program (Q1, Q2, Q3)

3. Evaluation Report

1.1.1 Open Operating Grant Program (Q4)
1.2.6 National Anti-Drug Strategy Treatment Research Initiative (Q3)
2.1.2 Training Support Programs (Q3)
2.1.4 Canada Graduate Scholarships Program (Q3)
2.1.6 Strategic Training Support Programs (Q3)
3.1.2 Networks of Centers of Excellence Program (Q4)